Get the Stockscreener App
2.425
2.32%
0.055
Annexon Inc stock is traded at $2.425, with a volume of 219.29K.
It is up +2.32% in the last 24 hours and up +1.89% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$2.37
Open:
$2.4
24h Volume:
219.29K
Relative Volume:
0.14
Market Cap:
$266.06M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.3701
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
+1.04%
1M Performance:
+1.89%
6M Performance:
-42.81%
1Y Performance:
-58.69%
1-Day Range:
$2.34
$2.46
1-Week Range:
$2.2104
$2.53
52-Week Range:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.425 | 274.29M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.29 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.80 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.34 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.41 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.31 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon Inc. Stock Analysis and ForecastPowerful growth strategies - Autocar Professional
What analysts say about Annexon Inc. stockFast-track wealth growth - jammulinksnews.com
What drives Annexon Inc. stock priceRapidly expanding wealth - jammulinksnews.com
Is Annexon Inc. a good long term investmentHigh-performance investment picks - Autocar Professional
Why Annexon Inc. stock attracts strong analyst attentionCapital Doubling Tips - Newser
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - 富途牛牛
Is Annexon Inc. stock a growth or value playHigh Reward Risk Balanced Trading - Newser
Annexon Inc (ANNX) Stock: A Comprehensive 52-Week Review - investchronicle.com
Annexon EVP Yednock sells $2.9k in shares By Investing.com - Investing.com South Africa
Annexon EVP Yednock sells $2.9k in shares - Investing.com Australia
What makes Annexon Inc. stock price move sharplyTop Performing Stocks - Newser
How Annexon Inc. stock performs during market volatilityWeekly Big Movers - Newser
Annexon: Lead GBS Therapy Stokes Near Term Potential (NASDAQ:ANNX) - Seeking Alpha
Annexon Target of Unusually Large Options Trading (NASDAQ:ANNX) - Defense World
Annexon (NASDAQ:ANNX) Stock Price Down 0.7% – Should You Sell? - Defense World
Annexon says enrollment of Phase 3 Archer II Trial expected to be completed in Q3 2025 - MarketScreener
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrop - GuruFocus
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) - GlobeNewswire
Bank of America Corp DE Sells 137,220 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Park Avenue Securities LLC - Defense World
Market Highlights: Annexon Inc (ANNX) Ends on a Low Note at 2.49 - DWinneX
49,062 Shares in Annexon, Inc. (NASDAQ:ANNX) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by California State Teachers Retirement System - Defense World
Cantor Fitzgerald Estimates Annexon FY2026 Earnings - Defense World
Annexon Biosciences Holds Annual Stockholders Meeting - TipRanks
Two Sigma Advisers LP Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Squarepoint Ops LLC Sells 49,438 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annexon Inc Stock (ANNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Jul 14 '25 |
Sale |
2.58 |
1,117 |
2,882 |
121,616 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Jul 14 '25 |
Sale |
2.61 |
853 |
2,226 |
130,689 |
4.56%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):